Major Investor 5AM Ventures Exits Rallybio with $4.07M Share Sale Following Failed Merger
RLYB has more than doubled off its 52-week low of $2.16.
Summary
5AM Ventures, a major institutional investor, has fully sold its stake in Rallybio Corp for $4.07 million, coinciding with the termination of the company's reverse merger.
Key Events · Ownership and Investor Activity · RLYB
-
Institutional Investor Exits
5AM Ventures, a significant institutional investor, sold all of its 291,788 shares of Rallybio common stock, indicating a complete divestment of their position.
-
Significant Share Sale Value
The shares were sold in open market transactions on May 4, 2026, at a weighted average price of $13.95 per share, totaling approximately $4.07 million.
-
Coincides with Failed Merger
This complete divestment occurred on the same day Rallybio announced the termination of its reverse merger agreement with Candid Therapeutics, suggesting a reaction to the failed strategic event.
Analysis · RLYB · Life Sciences
This Schedule 13D/A reports that 5AM Ventures, a significant institutional investor, has fully divested its stake in Rallybio Corp by selling 291,788 shares for approximately $4.07 million. This complete exit, representing over 5% of the company's market capitalization, occurred on May 4, 2026, the same day Rallybio announced the termination of its reverse merger agreement with Candid Therapeutics. The timing suggests a loss of confidence from a major investor following the collapse of the strategic transaction, which could put further pressure on the stock.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $14.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77M. The 52-week trading range was $2.16 to $15.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.